Printer Friendly

Advanced Tissue Sciences receives patent for growing living cartilage with mesenchymal stem cells.

Advanced Tissue Sciences, Inc. (La Jolla, CA; 619-713-7802) announced the issuance of United States Patent 5,902,741 entitled "Three-Dimensional Cartilage Cultures." This patent covers three-dimensional cartilage compositions and methods of growing living cartilage in vitro by inoculating cartilage-producing cells onto biocompatible, non-living scaffolds. The cartilage-producing cells claimed include precursor cells such as mesenchymal stem cells, chondroprogenitor cells, and umbilical cord cells as well as mature chondrocytes and fibroblasts. This patent extends through March 2016.

The newly issued patent is complementary to the company's patent 5,842,477 entitled "Method for Repairing Cartilage," which issued in December of 1998. This method patent covers use of a three-dimensional scaffold along with cartilage-producing cells and a periosteal flap to repair a defect in vivo. The company's current patent position now includes 50 issued United States patents directly owned by or licensed to Advanced Tissue Sciences.

"The issuance of our cartilage patents is timely as we advance toward clinical trials," said Gail K. Naughton, PhD, president and chief operating officer. "Two-year follow-up on our preclinical trials on small animal models, preclinical studies in a large animal model, and our strengthened patent position make us, together with our joint venture partner, Smith & Nephew, well poised to advance the orthopedic products."

On April 15, 1999 Advanced Tissues Sciences was awarded a Small Business Innovation Research Program grant from the Department of Health and Human Services, Public Health Services. This grant, entitled "Enhancing In Vitro Cartilage Synthesis for Human Therapy," will fund development of a bioreactor that applies mechanical stresses to growing cartilage. The bioreactor is designed to stimulate matrix deposition to affect the organizational, structural, and functional properties of cartilage growth. Work funded by this grant is directed at the development of cartilage products for reconstructive applications.

Advanced Tissue Sciences is a tissue engineering company utilizing its proprietary core technology to develop and manufacture human-based tissue products for tissue repair and transplantation. The company, through its Dermagraft Joint Venture with Smith & Nephew, currently has two products on the market, TransCyte(TM), a temporary covering for third-degree (full- thickness) and second-degree (partial-thickness) burns, and Dermagraft, a living dermal replacement for the treatment of diabetic foot ulcers (currently available in Canada and the United Kingdom). The company is conducting a multi-center trial for Dermagraft for treating diabetic foot ulcers in the United States and is pursuing additional indications for Dermagraft, including venous and pressure ulcers through the Dermagraft Joint Venture. The company is also developing products for cartilage and cardiovascular applications.
COPYRIGHT 1999 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1999 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:Advanced Tissue Sciences receives patent for growing living cartilage with mesenchymal stem cells.
Publication:BIOTECH Patent News
Geographic Code:1USA
Date:May 1, 1999
Previous Article:IntraTherapeutics signs licensing agreement with American BioMed for Vascular embolization microfilter technology.
Next Article:Incyte Prevails on Preliminary Injunction Request.

Related Articles
Advanced Tissue Sciences, MIT and Children's Hospital of Boston announce new tissue engineering patents
Osiris Therapeutics issued broad patent for inducing the formation of multiple connective tissues
Osiris Therapeutics issued broad patent covering role of stem cells in fat formation.
Osiris issued patent covering markers for production of human stem cells.
Osiris Therapeutics issued patent covering adult stem cells for tendon and muscle regeneration.
Osiris Therapeutics and Cambrex subsidiary BioWhittaker form collaboration for adult stem cells.
Culture of cells for tissue engineering.
Non-surgical stem-cell procedure relieves degenerative joint disease.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters